Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences Files Fourth Patent Lawsuit Against Cellectis

NEW YORK (GenomeWeb News) – Precision BioSciences today said it has filed a fourth lawsuit against Cellectis and a number of its affiliates alleging patent infringement.

The company filed its lawsuit in US District Court for the Eastern District of North Carolina claiming Cellectis infringes on US Patent No. 8,124,369, which relates to Precision Bio's Directed Nuclease Editor genome engineering technology.

The Research Triangle Park, N.C.-based genetic engineering company is asking for monetary damages, a permanent injunction against Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the US.

Precision Bio filed two lawsuits against the French firm last week as well as one in the fall.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.